• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Genscript Biotech (SEHK:1548) Could Be 46% Above Fair Value As Lilly TuneLab Deal Lands

    Simply Wall St·10/01/2026 10:12:51
    語音播報

    Genscript Biotech joins Lilly’s AI drug discovery network

    Genscript Biotech (SEHK:1548) has agreed to join Lilly TuneLab, supplying preferred-rate wet lab services that turn AI-generated drug discovery predictions into experimental data for member companies on the platform.

    The latest Lilly TuneLab agreement comes after a sharp share price run, with Genscript Biotech posting a 1-month share price return of 32.41% and a 90-day share price return of 241.14%, while the 1-year total shareholder return sits at 168.30%.

    Scan beyond Genscript Biotech and see which other AI-driven drug development players are gaining momentum with our hand-picked 133 healthcare AI stocks.

    A share price that has more than tripled in 90 days now trades above both analyst targets and one estimate of fair value. Is the market overreacting to Genscript Biotech’s AI and DNA platforms, or is it still underpricing them?

    Most Popular Narrative: 46% Overvalued

    Genscript Biotech last closed at HK$44.86, while the most followed narrative pegs fair value at HK$30.66. This implies the share price sits well above that estimate and places a lot of weight on the AI story and new equity capital.

    The CARVYKTI launch by Legend Biotech (GenScript's major subsidiary) is exceeding industry expectations, with operational breakeven and group-level profitability targeted by 2026, which is likely to drive higher equity income and improve GenScript's net margins and overall earnings trajectory.

    See why 3 investors see Genscript Biotech as 46% overvalued.

    Result: Fair Value of HK$30.66 (OVERVALUED)

    Still, the Genscript Biotech story can shift quickly if rising competition squeezes margins or if heavy R&D and capacity spending fails to translate into commercial payoff.

    Find out about the key risks to this Genscript Biotech narrative.

    Next Steps

    If this Genscript Biotech story feels pulled between excitement and caution, that is because it is. Act while sentiment is fresh, and weigh both sides by checking the 1 key reward and 1 important warning sign.

    Looking for more Genscript Biotech style investment ideas?

    If Genscript Biotech has your attention, do not stop at a single opportunity. Use targeted stock lists to pressure test your thesis and spot alternatives early.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.